LoRusso PM - Search Results

1

A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.

Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. Alousi AM, et al. Among authors: lorusso pm. Invest New Drugs. 2007 Apr;25(2):147-54. doi: 10.1007/s10637-006-9024-5. Epub 2006 Nov 11. Invest New Drugs. 2007. PMID: 17103044 Clinical Trial.

2

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.

LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH. LoRusso P, et al. Cancer Res. 1990 Aug 15;50(16):4900-5. Cancer Res. 1990. PMID: 2165850

3

Levels of 5-hydroxymethyl-2'-deoxyuridine in DNA from blood as a marker of breast cancer.

Djuric Z, Heilbrun LK, Simon MS, Smith D, Luongo DA, LoRusso PM, Martino S. Djuric Z, et al. Among authors: lorusso pm. Cancer. 1996 Feb 15;77(4):691-6. Cancer. 1996. PMID: 8616761

4

Comparative efficacy of DMP 840 against mouse and human solid tumor models.

LoRusso P, Demchik L, Dan M, Polin L, Gross JL, Corbett TH. LoRusso P, et al. Invest New Drugs. 1995;13(3):195-203. doi: 10.1007/BF00873800. Invest New Drugs. 1995. PMID: 8729946

5

Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.

Foster BJ, LoRusso PM, Poplin E, Zalupski M, Valdivieso M, Wozniak A, Flaherty L, Kasunic DA, Earhart RH, Baker LH. Foster BJ, et al. Among authors: lorusso pm. Invest New Drugs. 1996;13(4):321-6. doi: 10.1007/BF00873138. Invest New Drugs. 1996. PMID: 8824350 Clinical Trial.

6

Preclinical antitumor activity of CI-994.

LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR 3rd, Corbett TH. LoRusso PM, et al. Invest New Drugs. 1996;14(4):349-56. doi: 10.1007/BF00180810. Invest New Drugs. 1996. PMID: 9157069

7

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.

Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett TH. Polin L, et al. Invest New Drugs. 1997;15(2):99-108. doi: 10.1023/a:1005856605726. Invest New Drugs. 1997. PMID: 9220288

8

Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).

Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH. Foster BJ, et al. Among authors: lorusso pm. Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398. Invest New Drugs. 1997. PMID: 9387041

9

Preclinical anticancer activity of cryptophycin-8.

Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand RA, Lisow L, Golakoti T, Heltzel CE, Ogino J, Patterson GM, Moore RE. Corbett TH, et al. J Exp Ther Oncol. 1996 Mar;1(2):95-108. J Exp Ther Oncol. 1996. PMID: 9414393

10

Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.

Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V. Zalupski MM, et al. Invest New Drugs. 1998;16(1):93-6. doi: 10.1023/a:1006087114621. Invest New Drugs. 1998. PMID: 9740550 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters